• 1
    Bresciani M, Parisi C, Manghi G, Bonini S. The hygiene hypothesis: does it function worldwide? Curr Opin Allergy Clin Immunol 2005;5:147151.
  • 2
    Eder W, Von Mutius E. Hygiene hypothesis and endotoxin: what is the evidence? Curr Opin Allergy Clin Immunol 2004;4:113117.
  • 3
    Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998;102:558562.
  • 4
    Grun JL, Maurer PH. Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles: the role of endogenous interleukin 1 in proliferative responses. Cell Immunol 1989;121:134145.
  • 5
    Wohlleben G, Erb KJ. Atopic disorders: a vaccine around the corner? Trends Immunol 2001;22:618626.
  • 6
    Morris DL. WHO position paper on oral (sublingual) immunotherapy. Ann Allergy Asthma Immunol 1999;83:423424.
  • 7
    Wiedermann U. Mucosal immunity–mucosal tolerance. A strategy for treatment of allergic diseases. Chem Immunol Allergy 2003;82:1124.
  • 8
    Mercenier A, Pavan S, Pot B. Probiotics as biotherapeutic agents: present knowledge and future prospects. Curr Pharm Des 2003;9:175191.
  • 9
    Bjorksten B, Sepp E, Julge K, Voor T, Mikelsaar M. Allergy development and the intestinal microflora during the first year of life. J Allergy Clin Immunol 2001;108:516520.
  • 10
    Rautava S, Kalliomaki M, Isolauri E. New therapeutic strategy for combating the increasing burden of allergic disease: Probiotics – A Nutrition, Allergy, Mucosal Immunology and Intestinal Microbiota (NAMI) Research Group report. J Allergy Clin Immunol 2005;116:3137.
  • 11
    Kalliomaki M, Salminen S, Poussa T, Arvilommi H, Isolauri E. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet 2003;361:18691871.
  • 12
    Rosenfeldt V, Benfeldt E, Nielsen SD, Michaelsen KF, Jeppesen DL, Valerius NH et al. Effect of probiotic Lactobacillus strains in children with atopic dermatitis. J Allergy Clin Immunol 2003;111:389395.
  • 13
    Repa A, Grangette C, Daniel C, Hochreiter R, Hoffmann-Sommergruber K, Thalhamer J et al. Mucosal co-application of lactic acid bacteria and allergen induces counter-regulatory immune responses in a murine model of birch pollen allergy. Vaccine 2003;22:8795.
  • 14
    Grangette C, Muller-Alouf H, Goudercourt D, Geoffroy MC, Turneer M, Mercenier A. Mucosal immune responses and protection against tetanus toxin after intranasal immunization with recombinant Lactobacillus plantarum. Infect Immun 2001;69:15471553.
  • 15
    Hanniffy S, Wiedermann U, Repa A, Mercenier A, Daniel C, Fioramonti J et al. Potential and opportunities for use of recombinant lactic acid bacteria in human health. Adv Appl Microbiol 2004;56:164.
  • 16
    Hols P, Slos P, Dutot P, Reymund J, Chabot P, Delplace B et al. Efficient secretion of the model antigen M6-gp41E in Lactobacillus plantarum NCIMB 8826. Microbiology 1997;143:27332741.
  • 17
    Wells JM, Wilson PW, Le Page RW. Improved cloning vectors and transformation procedure for Lactococcus lactis. J Appl Bacteriol 1993;74:629636.
  • 18
    Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual, 2nd edn. New York: Cold Spring Harbor Laboratory, 1989.
  • 19
    Weiss C, Kramer B, Ebner C, Susani M, Briza P, Hoffmann-Sommergruber K et al. High-level expression of tree pollen isoallergens in Escherichia coli. Int Arch Allergy Immunol 1996;110:282287.
  • 20
    De Ruyter PG, Kuipers OP, De Vos WM. Controlled gene expression systems for Lactococcus lactis with the food-grade inducer nisin. Appl Environ Microbiol 1996;62:36623667.
  • 21
    Pavan S, Hols P, Delcour J, Geoffroy MC, Grangette C, Kleerebezem M et al. Adaptation of the nisin-controlled expression system in Lactobacillus plantarum: a tool to study in vivo biological effects. Appl Environ Microbiol 2000;66:44274432.
  • 22
    Kuipers OP, Beerthuyzen MM, Siezen RJ, De Vos WM. Characterization of the nisin gene cluster nisABTCIPR of Lactococcus lactis. Requirement of expression of the nisA and nisI genes for development of immunity. Eur J Biochem 1993;216:281291.
  • 23
    Jarolim E, Tejkl M, Rohac M, Schlerka G, Scheiner O, Kraft D et al. Monoclonal antibodies against birch pollen allergens: characterization by immunoblotting and use for single-step affinity purification of the major allergen Bet v I. Int Arch Allergy Appl Immunol 1989;90:5460.
  • 24
    Wiedermann U, Jahn-Schmid B, Fritsch R, Bauer L, Renz H, Kraft D et al. Effects of adjuvants on the immune response to allergens in a murine model of allergen inhalation: cholera toxin induces a Th1-like response to Bet v 1, the major birch pollen allergen. Clin Exp Immunol 1998;111:144151.
  • 25
    Repa A, Wild C, Hufnagl K, Winkler B, Bohle B, Pollak A et al. Influence of the route of sensitization on local and systemic immune responses in a murine model of type I allergy. Clin Exp Immunol 2004;137:1218.
  • 26
    Romagnani S. Immunologic influences on allergy and the TH1/TH2 balance. J Allergy Clin Immunol 2004;113:395400.
  • 27
    Kruisselbrink A, Heijne Den Bak-Glashouwer MJ, Havenith CE, Thole JE, Janssen R. Recombinant Lactobacillus plantarum inhibits house dust mite-specific T-cell responses. Clin Exp Immunol 2001;126:28.
  • 28
    Chatel JM, Nouaille S, Adel-Patient K, Le Loir Y, Boe H, Gruss A et al. Characterization of a Lactococcus lactis strain that secretes a major epitope of bovine beta-lactoglobulin and evaluation of its immunogenicity in mice. Appl Environ Microbiol 2003;69:66206627.
  • 29
    Scheppler L, Vogel M, Marti P, Muller L, Miescher SM, Stadler BM. Intranasal immunisation using recombinant Lactobacillus johnsonii as a new strategy to prevent allergic disease. Vaccine 2005;23:11261134.
  • 30
    Adel-Patient K, Ah-Leung S, Creminon C, Nouaille S, Chatel JM, Langella P et al. Oral administration of recombinant Lactococcus lactis expressing bovine beta-lactoglobulin partially prevents mice from sensitization. Clin Exp Allergy 2005;35:539546.
  • 31
    Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005;11:S4553.
  • 32
    Almeida AJ, Alpar HO. Nasal delivery of vaccines. J Drug Target 1996;3:455467.
  • 33
    Eyles JE, Bramwell VW, Williamson ED, Alpar HO. Microsphere translocation and immunopotentiation in systemic tissues following intranasal administration. Vaccine 2001;19:473242.
  • 34
    Valenta R. The future of antigen-specific immunotherapy of allergy. Nat Rev Immunol 2002;2:446453.
  • 35
    Sur S, Wild JS, Choudhury BK, Sur N, Alam R, Klinman DM. Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides. J Immunol 1999;162:62846293.
  • 36
    Jilek S, Barbey C, Spertini F, Corthesy B. Antigen-independent suppression of the allergic immune response to bee venom phospholipase A(2) by DNA vaccination in CBA/J mice. J Immunol 2001;166:36123621.
  • 37
    Brandtzaeg P, Baekkevold ES, Farstad IN, Jahnsen FL, Johansen FE, Nilsen EM et al. Regional specialization in the mucosal immune system: what happens in the microcompartments? Immunol Today 1999;20:141151.
  • 38
    Platts-Mills TA, Von Maur RK, Ishizaka K, Norman PS, Lichtenstein LM. IgA and IgG anti-ragweed antibodies in nasal secretions. Quantitative measurements of antibodies and correlation with inhibition of histamine release. J Clin Invest 1976;57:10411050.
  • 39
    Aghayan-Ugurluoglu R, Ball T, Vrtala S, Schweiger C, Kraft D, Valenta R. Dissociation of allergen-specific IgE and IgA responses in sera and tears of pollen-allergic patients: a study performed with purified recombinant pollen allergens. J Allergy Clin Immunol 2000;105:803813.
  • 40
    Bottcher MF, Haggstrom P, Bjorksten B, Jenmalm MC. Total and allergen-specific immunoglobulin A levels in saliva in relation to the development of allergy in infants up to 2 years of age. Clin Exp Allergy 2002;32:12931298.
  • 41
    Bolhaar ST, Tiemessen MM, Zuidmeer L, Van Leeuwen A, Hoffmann-Sommergruber K, Bruijnzeel-Koomen CA et al. Efficacy of birch-pollen immunotherapy on cross-reactive food allergy confirmed by skin tests and double-blind food challenges. Clin Exp Allergy 2004;34:761769.